Please assess the completion status of the following clinical trial:

Trial Title: Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Post menopausal women,~* Ages 35 or older,~* Frequent moderate to severe hot flushes,~* Qualifying general medical health~Exclusion Criteria:~* Disqualifying gynecological disorders,~* Disqualifying dermatological disorders,~* Disqualifying concurrent conditions

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo transdermal three 90 μL sprays (Type: PLACEBO_COMPARATOR): Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Placebo transdermal two 90 μL sprays (Type: PLACEBO_COMPARATOR): Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Placebo transdermal one 90 μL spray (Type: PLACEBO_COMPARATOR): Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
- Estradiol transdermal three 90 μL sprays (Type: ACTIVE_COMPARATOR): Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Estradiol transdermal two 90 μL sprays (Type: ACTIVE_COMPARATOR): Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
- Estradiol transdermal one 90 μL spray (Type: ACTIVE_COMPARATOR): Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator

Based on this trial design, predict the completion outcome and termination type (if applicable).